| Bioactivity | SX-682 is an orally bioavailable, potent allosteric inhibitor of CXCR1 and CXCR2. SX-682 can block tumor myeloid-derived suppressor cells (MDSCs) recruitment and enhance T cell activation and antitumor immunity[1]. | ||||||||||||
| In Vivo | SX-682 (50 mg/kg; orally; twice a day on a Monday through Friday) has Meager to moderate effects as single agents on CRPC progression was observed, yet combination with ICB produced strong efficacy[2]. Animal Model: | ||||||||||||
| Name | SX-682 | ||||||||||||
| CAS | 1648843-04-2 | ||||||||||||
| Formula | C19H14BF4N3O4S | ||||||||||||
| Molar Mass | 467.20 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Sun L, et al. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. JCI Insight. 2019 Apr 4;4(7). [2]. Lu X, et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature. 2017 Mar 30;543(7647):728-732. |
SX-682
CAS: 1648843-04-2 F: C19H14BF4N3O4S W: 467.20
SX-682 is an orally bioavailable, potent allosteric inhibitor of CXCR1 and CXCR2. SX-682 can block tumor myeloid-derived
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.